CDK4/6 inhibitors, known to control cell cycle progression, have shown robust antitumor activity in HR-positive, HER2-negative BC, significantly prolonging progression-free survival (PFS) and overall survival (OS) in advanced disease [31, 32]. This evidence concerns the gene ERBB2 and breast cancer.